{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T18:07:37Z","timestamp":1790446057478,"version":"4.1.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:00:00Z","timestamp":1761868800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007132","name":"Korea Otsuka Pharmaceutical Co., Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007132","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,30]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Delamanid has demonstrated potential in the treatment of multidrug-resistant (MDR) or rifampicin-resistant tuberculosis (TB); however, real-world data on its effectiveness and safety remain limited.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective cohort study enrolled patients with pulmonary MDR-TB who were treated with a delamanid-containing longer regimen under programmatic conditions in South Korea between 2017 and 2021. Data on delamanid usage, safety, and efficacy were analyzed separately.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 147 patients were included in the usage and safety analyses (mean age, 50.7 years; 60.5% male). Adherence to delamanid was high, with a median adherence of 100.0%; 98.6% (n = 145) of the patients received more than 80% of the prescribed dose. Delamanid-related adverse events (AEs) occurred in 44.2% (n = 65) of patients, with the most common AEs being nausea (10.9%), pruritus (6.8%), and QT interval prolongation (6.1%). Serious delamanid-related AEs were reported in 4.1% (n = 6) of the patients, and QTcF intervals exceeding 500\u2005ms were observed in 6.8% (n = 10) during treatment. For the efficacy analysis, 105 and 122 patients were included in the treatment response (at the end of delamanid treatment) and treatment outcome (at the end of MDR-TB treatment) evaluations, respectively. Among those who were culture-positive at baseline, 92.0% achieved sputum culture conversion during delamanid treatment. The overall treatment success rate was 86.9%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Delamanid demonstrated favorable safety and efficacy profiles for MDR-TB treatment under programmatic conditions, providing valuable and up-to-date evidence supporting its promising role in MDR-TB management.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofaf669","type":"journal-article","created":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:23:54Z","timestamp":1761830634000},"source":"Crossref","is-referenced-by-count":1,"title":["A Prospective Cohort Study on the Usage, Safety, and Efficacy of Delamanid in Patients With Pulmonary Multidrug-Resistant Tuberculosis in South Korea"],"prefix":"10.1093","volume":"12","author":[{"given":"Jeongha","family":"Mok","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Pusan National University Hospital, Pusan National University School of Medicine , Busan ,","place":["Republic of Korea"]},{"name":"Biomedical Research Institute, Pusan National University Hospital , Busan ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haesook","family":"Seo","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Seoul Metropolitan Seobuk Hospital , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youngsoo","family":"Cho","sequence":"additional","affiliation":[{"name":"Department of Tuberculosis, Seoul Metropolitan Seobuk Hospital , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taehoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Ulsan University Hospital, University of Ulsan College of Medicine , Ulsan ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1763-5366","authenticated-orcid":false,"given":"Sang-Ha","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Yonsei University Wonju College of Medicine , Wonju ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hye Kyeong","family":"Park","sequence":"additional","affiliation":[{"name":"Division of Pulmonary and Critical Care Medicine, Incheon Medical Center , Incheon ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1219-0070","authenticated-orcid":false,"given":"Jee Youn","family":"Oh","sequence":"additional","affiliation":[{"name":"Divsion of Pulmonary, Allergy, and Critical Care Medicine, Department of Internal Medicine, Korea University College of Medicine, Korea University Guro Hospital , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae Sun","family":"Shim","sequence":"additional","affiliation":[{"name":"Department of Pulmonary and Critical Care Medicine, Asan Medical Center, University of Ulsan College of Medicine , Seoul ,","place":["Republic of Korea"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,10,31]]},"reference":[{"key":"2025111908370945900_ofaf669-B1","volume-title":"Global tuberculosis report 2024","year":"2024"},{"key":"2025111908370945900_ofaf669-B2","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ijid.2020.01.042","article-title":"MDR\/XDR-TB management of patients and contacts: challenges facing the new decade. The 2020 clinical update by the Global Tuberculosis Network","volume":"92S","author":"Migliori","year":"2020","journal-title":"Int J Infect Dis"},{"key":"2025111908370945900_ofaf669-B3","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S2213-2600(14)70031-1","article-title":"Global control of tuberculosis: from extensively drug-resistant to untreatable tuberculosis","volume":"2","author":"Dheda","year":"2014","journal-title":"Lancet Respir Med"},{"key":"2025111908370945900_ofaf669-B4","doi-asserted-by":"crossref","first-page":"e466","DOI":"10.1371\/journal.pmed.0030466","article-title":"OPC-67683, a nitro-dihydroimidazooxazole derivative with promising action against tuberculosis in vitro and in mice","volume":"3","author":"Matsumoto","year":"2006","journal-title":"PLoS Med"},{"key":"2025111908370945900_ofaf669-B5","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2174\/092986707781368496","article-title":"Novel agents in the management of Mycobacterium tuberculosis disease","volume":"14","author":"Barry","year":"2007","journal-title":"Curr Med Chem"},{"key":"2025111908370945900_ofaf669-B6","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1056\/NEJMoa1112433","article-title":"Delamanid for multidrug-resistant pulmonary tuberculosis","volume":"366","author":"Gler","year":"2012","journal-title":"N Engl J Med"},{"key":"2025111908370945900_ofaf669-B7","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1183\/09031936.00125812","article-title":"Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis","volume":"41","author":"Skripconoka","year":"2013","journal-title":"Eur Respir J"},{"key":"2025111908370945900_ofaf669-B8","volume-title":"The use of delamanid in the treatment of multidrug-resistant tuberculosis: interim policy guidance","year":"2014"},{"key":"2025111908370945900_ofaf669-B9","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(18)31644-1","article-title":"Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis","volume":"392","author":"Ahmad","year":"2018","journal-title":"Lancet"},{"key":"2025111908370945900_ofaf669-B10","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S2213-2600(18)30426-0","article-title":"Efficacy and safety of delamanid in combination with an optimised background regimen for treatment of multidrug-resistant tuberculosis: a multicentre, randomised, double-blind, placebo-controlled, parallel group phase 3 trial","volume":"7","author":"von Groote-Bidlingmaier","year":"2019","journal-title":"Lancet Respir Med"},{"key":"2025111908370945900_ofaf669-B11","volume-title":"WHO Consolidated guidelines on drug-resistant tuberculosis treatment","year":"2019"},{"key":"2025111908370945900_ofaf669-B12","author":"Joint Committee for the Revision of Korean Guidelines for Tuberculosis"},{"key":"2025111908370945900_ofaf669-B13"},{"key":"2025111908370945900_ofaf669-B14","author":"Medical Dictionary for Regulatory Activities"},{"key":"2025111908370945900_ofaf669-B15","volume-title":"Definitions and reporting framework for tuberculosis-2013 revision","year":"2013"},{"key":"2025111908370945900_ofaf669-B16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1093\/cid\/ciz1084","article-title":"Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis","volume":"71","author":"Seung","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2025111908370945900_ofaf669-B17","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/cid\/ciab304","article-title":"Outcomes of multidrug-resistant tuberculosis treated with bedaquiline or delamanid","volume":"73","author":"Hwang","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025111908370945900_ofaf669-B18","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1016\/j.ijid.2022.02.043","article-title":"Delamanid-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"124","author":"Nasiri","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2025111908370945900_ofaf669-B19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.5588\/ijtld.18.0658","article-title":"Multidrug-resistant tuberculosis in South Korea: a retrospective analysis of national registry data in 2011\u20132015","volume":"23","author":"Lee","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025111908370945900_ofaf669-B20","doi-asserted-by":"crossref","first-page":"174","DOI":"10.5588\/ijtld.18.0295","article-title":"Multidrug-resistant tuberculosis over 20 years at a referral hospital in South Korea: trends and outcomes","volume":"23","author":"Kwak","year":"2019","journal-title":"Int J Tuberc Lung Dis"},{"key":"2025111908370945900_ofaf669-B21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.4046\/trd.2020.0093","article-title":"Treatment outcomes of patients with multidrug-resistant tuberculosis: comparison of pre- and post-Public-Private Mix periods","volume":"84","author":"Kang","year":"2021","journal-title":"Tuberc Respir Dis (Seoul)"},{"key":"2025111908370945900_ofaf669-B22","doi-asserted-by":"crossref","first-page":"1901522","DOI":"10.1183\/13993003.01522-2019","article-title":"Surveillance of adverse events in the treatment of drug-resistant tuberculosis: first global report","volume":"54","author":"Borisov","year":"2019","journal-title":"Eur Respir J"},{"key":"2025111908370945900_ofaf669-B23","doi-asserted-by":"crossref","first-page":"274","DOI":"10.5588\/ijtldopen.24.0113","article-title":"Real-life use of delamanid: results from the European post-authorisation safety study","volume":"1","author":"Sch\u00f6nfeld","year":"2024","journal-title":"IJTLD Open"},{"key":"2025111908370945900_ofaf669-B24","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12879-022-07955-6","article-title":"A prospective patient registry to monitor safety, effectiveness, and utilisation of bedaquiline in patients with multidrug-resistant tuberculosis in South Korea","volume":"23","author":"Shim","year":"2023","journal-title":"BMC Infect Dis"},{"key":"2025111908370945900_ofaf669-B25","doi-asserted-by":"crossref","first-page":"e20210384","DOI":"10.36416\/1806-3756\/e20210384","article-title":"Bedaquiline-containing regimens and multidrug-resistant tuberculosis: a systematic review and meta-analysis","volume":"48","author":"Hatami","year":"2022","journal-title":"J Bras Pneumol"},{"key":"2025111908370945900_ofaf669-B26","author":"Joint Committee for the Revision of Korean Guidelines for Tuberculosis"},{"key":"2025111908370945900_ofaf669-B27","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1016\/S0140-6736(22)01883-9","article-title":"9 months of delamanid, linezolid, levofloxacin, and pyrazinamide versus conventional therapy for treatment of fluoroquinolone-sensitive multidrug-resistant tuberculosis (MDR-END): a multicentre, randomised, open-label phase 2\/3 non-inferiority trial in South Korea","volume":"400","author":"Mok","year":"2022","journal-title":"Lancet"},{"key":"2025111908370945900_ofaf669-B28","volume-title":"Module 4: treatment and care","author":"WHO consolidated guidelines on tuberculosis","year":"2025"},{"key":"2025111908370945900_ofaf669-B29","doi-asserted-by":"crossref","first-page":"e972","DOI":"10.1016\/S2666-5247(23)00172-6","article-title":"Bedaquiline resistance in patients with drug-resistant tuberculosis in Cape Town, South Africa: a retrospective longitudinal cohort study","volume":"4","author":"Derendinger","year":"2023","journal-title":"Lancet Microbe"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofaf669\/65045536\/ofaf669.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/11\/ofaf669\/65045536\/ofaf669.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/12\/11\/ofaf669\/65045536\/ofaf669.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:37:16Z","timestamp":1763559436000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofaf669\/8307146"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,30]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,10,30]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofaf669","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,30]]},"article-number":"ofaf669"}}